biOasis: Preclinical Proof of Concept Establishes the Foundation for Lucrative Licensing Model For the Transport of Therapeutic Agents Across the Blood Brain Barrier
SPOKANE, WA / ACCESSWIRE / October 24, 2016 / Rising Tide Equity, LLC announced today the release of its Initial Equity Report on biOasis Technologies Inc. (OTCQB: BIOAF, TSX-V: BTI.V), titled "biOasis: Preclinical Proof of Concept Establishes the Foundation for Lucrative Licensing Model for the Transport of Therapeutic Agents Across the Blood Brain Barrier".
biOasis is an early stage biopharmaceutical company focused on research, development and commercialization of technologies and products intended for the treatment of central nervous system ("CNS") diseases and diseases of the brain. The Company is currently engaged in the development of the "Transcend" platform for the transport of therapeutic agents across the blood brain barrier ("BBB").
"CNS disorders affect one in six people and all treatments are hindered by their inability to effectively transport drugs through the BBB," says Josh McGuire, general partner at Rising Tide Equity. "biOasis' Transcend platform has demonstrated clinical success in all in-vivo trials to date. With over 35 patents and multiple licensing partners in place, including leaders such as Astellas, Vaccinex, and development partners such as MedImmune, the company is well positioned to capitalize on their unique ability to deliver lifesaving therapies across the blood brain barrier."
This positioning is echoed by company CEO, Rob Hutchison who states, "The biOasis business model is based on the strength of our core assets, the intellectual property that is protected by our broad patent portfolio. Over the past seven years we have been focused on one goal, conducting extensive research programs to secure patents that enable us to commercialize our Transcend technology."
The global CNS therapeutics market is driven by the increasing incidence of CNS disorders, aging population, rising healthcare spending and the development of late stage drugs. Total market size is estimated to reach $129 Billion by 2020. At the present time, there exists the need for safe and effective drugs that overcome the limitations of the current generation of CNS treatments. More importantly, the greater need is finding a means of transporting current and future CNS treatments across the BBB.
The complete Rising Tide Equity Report, including important disclosures, is available at no cost on the Rising Tide Equity Research website, https://www.risingtideequity.com/category/bioasis/.
About Rising Tide Equity:
Rising Tide Equity is an Evidence Based Investment group dedicated to content creation and global dissemination for publicly traded companies. Our eclectic management team, with over 50 years in the capital markets, uses an Evidence Based Investing approach to filter out noise and identify compelling investments. At Rising Tide Equity, we use reasoned analysis to evaluate each company, examining the fundamental characteristics, market potential, and opportunity for further growth while engaging company leadership to assess their ability to achieve corporate goals. To learn more about Rising Tide Equity Research, visit our website, www.risingtideequity.com.
Disclaimer: https://www.risingtideequity.com/disclaimer/
SOURCE: Rising Tide Equity